Liminatus Pharma, Inc.
LIMN
$3.84
$0.205.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,342.10% | -243.11% | -3,454.79% | -203.19% | 104.17% |
| Total Depreciation and Amortization | -28.57% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.39% | -- | -- | -- | -- |
| Change in Net Operating Assets | 105.47% | -633.19% | 337.26% | -69.87% | -575.64% |
| Cash from Operations | 89.00% | -1,164.30% | -174.91% | -191.41% | -698.38% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | 100.00% | 86.67% |
| Cash from Investing | -- | -- | 100.00% | 98.36% | 86.67% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | 61.92% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.94% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 148.19% | -- | -- | -100.00% | -10,632.50% |
| Cash from Financing | -79.85% | 402.85% | -100.00% | -100.00% | 368.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.88% | 7,436.45% | -4,259.14% | -4,857.36% | 425.58% |